Skip to main content
Clinical Trials/NCT04445051
NCT04445051
Completed
Not Applicable

Exploratory Investigation on Performance and Safety of New Intermittent Catheters in Healthy Volunteers

Coloplast A/S1 site in 1 country30 target enrollmentMarch 1, 2020

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Retention, Urinary
Sponsor
Coloplast A/S
Enrollment
30
Locations
1
Primary Endpoint
Residual Urine at 1st Flow-stop
Status
Completed
Last Updated
2 years ago

Overview

Brief Summary

Investigation of non-CE marked intermittent catheters. The study was a randomized, single blinded, cross-over investigation comparing two new catheters with a comparator catheter in 30 adult healthy volunteers.

Detailed Description

The CP322 study investigated a novel non-CE marked intermittent catheter for males and females, designed in two different variants, Variant 1 and Variant 2, respectively. The study was conducted in Denmark and was a randomized, single blinded, cross-over investigation comparing the two new variant catheters with a comparator catheter in 30 adult healthy volunteers. For each participant, the study thus contained three test visits/treatment arms (Comparator, Variant 1 and Variant 2, respectively), to which the 30 participants were randomized using a randomization sequence of six (i.e., there were six different random options for the order in which the participants tested the three catheters). There were 4-14 days between the test visits.

Registry
clinicaltrials.gov
Start Date
March 1, 2020
End Date
September 1, 2020
Last Updated
2 years ago
Study Type
Interventional
Study Design
Crossover
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Minimum 18 years of age and with full legal capacity
  • Written informed consent and signed letter of authority and secrecy agreement given
  • Willing to comply with not using analgesics 1 up to 24 hours prior to catheterization visits
  • Urine Multistix negative for erythrocytes (hematuria)

Exclusion Criteria

  • Participation in any other clinical investigations during this investigation
  • Known hypersensitivity towards any of the test products
  • Symptoms of urinary tract infection (UTI) (Investigators judgement)
  • Pregnancy or breastfeeding

Outcomes

Primary Outcomes

Residual Urine at 1st Flow-stop

Time Frame: Immediately after the procedure/catheterization, up to 5 min.

The residual urine at 1st flow-stop during catheterization (performed by a nurse) represents the volume of urine left in the bladder, the first time the urine stops running out of the catheter during bladder emptying/urination. This was assessed using a pressure sensor with time-logged weighing, meaning that a flow-stop was registered measuring the hydrostatic pressure at the outlet of an intermittent urinary catheter. Simultaneously, the collected urine was weighed and converted to volume, and the residual volume at first flow stop was calculated as the difference between the total urine volume collected and the volume collected at the first flow-stop.

Secondary Outcomes

  • Post-void Residual Urine(Immediately after the procedure/catheterization, up to 15 min.)
  • Withdrawal Discomfort(Immediately after the procedure/catheterization, up to 5 min.)
  • Post-catheterization Urination Discomfort(Immediately after the first normal void following the procedure/catheterization, up to 5 min.)
  • Catheterization Insertion Discomfort(Immediately after the procedure/catheterization, up to 5 min.)
  • Catheterization Urination Discomfort(Immediately after the procedure/catheterization, up to 5 min.)
  • Overall Catheterization Discomfort(Immediately after the procedure/catheterization, up to 5 min.)

Study Sites (1)

Loading locations...

Similar Trials